Table 3. Characteristics of patients intended to be treated with chemotherapy.

	CD20 positive n=55	CD20 negative n=81	P
Sex (M/F)	27/28	41/40	0.861
Age (median, range)	37.0 (18-64)	35.0 (18-61)	0.401
WBC (median, range)	10.85 (1.58-379.37)	8.66 (1.2-563.57)	0.928
HB (median, range)	92.0 (39.2-152.0)	85.5 (38.0-154.0)	0.193
PLT (median, range)	34.5(6.0-272.0)	58.0(7.0-391.5)	0.029*
EMD (n, (%))	31 (56.3)	26 (32.1)	0.005**
Hepatosplenomegaly and lymphadeopathy (n, (%))	26(47.3)	25 (30.9)	0.052
CNSL (n, (%))	6 (10.9)	3 (3.7)	0.157
Cytogenetic risk (n, (%))			0.123
Low	1 (1.8)	0 (0)
Intermediate	42 (76.4)	58 (71.6)
High and very high	12 (21.8)	23 (28.4)
Risk stratification			0.765
Standard risk	15(27.3)	24 (29.6)
High risk	40(72.7)	57 (70.4)
Consolidation regimen			0.500
HyperCVAD	15(27.3)	18 (22.2)
Non-hyperCVAD	40(72.7)	63 (77.8)